Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice.

Trial Profile

Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms RE-CHUT
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Aug 2012 Actual patient number changed from 91 to 97 as reported by ClinicalTrials.gov.
    • 06 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top